繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Photocure ASA报告第二季度业绩

2025-07-30 23:36

  • Photocure ASA press release (OTCPK:PHCUF): Hexvix/Cysview revenues of NOK 135.6 million in the second quarter of 2025 (Q2 2024: NOK 122.4 million). 
  • EBITDA of NOK 14.8 million (Q2 2024: NOK 27.8 million, including a milestone payment of NOK 21.6 million) for the company. 
  • Photocure expects product revenue growth in the range of 7% to 11% and year-over-year EBITDA improvement in 2025.
  • While the company is not providing a specific EBITDA guidance range, Photocure expects continued operating leverage flow-through in its core commercial business and significant growth in milestones this year.

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。